ZA200300549B - Dementia remedies containing 2-aryl-8-oxidihydropurine derivatives as the active ingredient. - Google Patents

Dementia remedies containing 2-aryl-8-oxidihydropurine derivatives as the active ingredient. Download PDF

Info

Publication number
ZA200300549B
ZA200300549B ZA200300549A ZA200300549A ZA200300549B ZA 200300549 B ZA200300549 B ZA 200300549B ZA 200300549 A ZA200300549 A ZA 200300549A ZA 200300549 A ZA200300549 A ZA 200300549A ZA 200300549 B ZA200300549 B ZA 200300549B
Authority
ZA
South Africa
Prior art keywords
group
alkyl
dementia
amino
medicine
Prior art date
Application number
ZA200300549A
Other languages
English (en)
Inventor
Kiyoshi Furukawa
Satoshi Kurumiya
Takashi Hashimoto
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of ZA200300549B publication Critical patent/ZA200300549B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200300549A 2000-07-31 2003-01-21 Dementia remedies containing 2-aryl-8-oxidihydropurine derivatives as the active ingredient. ZA200300549B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000230209 2000-07-31

Publications (1)

Publication Number Publication Date
ZA200300549B true ZA200300549B (en) 2003-08-19

Family

ID=18723200

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200300549A ZA200300549B (en) 2000-07-31 2003-01-21 Dementia remedies containing 2-aryl-8-oxidihydropurine derivatives as the active ingredient.

Country Status (19)

Country Link
US (1) US6962921B2 (no)
EP (1) EP1306378A4 (no)
KR (1) KR100829297B1 (no)
CN (1) CN1247578C (no)
AU (1) AU7278701A (no)
BR (1) BR0112881A (no)
CA (1) CA2416706C (no)
CZ (1) CZ2003234A3 (no)
HK (1) HK1054231A1 (no)
HU (1) HUP0303714A3 (no)
IL (1) IL154049A0 (no)
MX (1) MXPA03000861A (no)
NO (1) NO20030474L (no)
NZ (1) NZ523812A (no)
PL (1) PL363870A1 (no)
RU (1) RU2277096C2 (no)
SK (1) SK1292003A3 (no)
WO (1) WO2002010167A1 (no)
ZA (1) ZA200300549B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7760101B2 (en) * 2008-06-20 2010-07-20 Kimberly-Clark Worldwide, Inc. Method of reducing sensor corrosion in absorbent articles
EP2476682B1 (en) * 2009-09-09 2017-04-26 Sumitomo Dainippon Pharma Co., Ltd. 8-oxodihydropurine derivative
US20140301947A1 (en) 2011-06-06 2014-10-09 Imperial Innovations Limited Methods to predict binding affinity of tspo imaging agents to tspo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
CA2112487C (en) * 1991-06-26 2003-04-15 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
NZ329798A (en) * 1996-07-03 1999-04-29 Japan Energy Corp Purine derivatives their tautomers and salts thereof and interferon secretion inducers, antiviral agents and anticancer drugs containing the same
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
JP3814125B2 (ja) * 1999-06-02 2006-08-23 大日本住友製薬株式会社 2−アリール−8−オキソジヒドロプリン誘導体からなる医薬

Also Published As

Publication number Publication date
NO20030474L (no) 2003-03-27
NO20030474D0 (no) 2003-01-30
AU7278701A (en) 2002-02-13
KR20030019634A (ko) 2003-03-06
EP1306378A1 (en) 2003-05-02
CN1247578C (zh) 2006-03-29
CZ2003234A3 (cs) 2003-05-14
IL154049A0 (en) 2003-07-31
US6962921B2 (en) 2005-11-08
MXPA03000861A (es) 2004-04-05
CA2416706C (en) 2009-04-07
WO2002010167A1 (fr) 2002-02-07
EP1306378A4 (en) 2005-02-09
NZ523812A (en) 2004-07-30
HUP0303714A2 (hu) 2004-03-01
CN1466587A (zh) 2004-01-07
RU2277096C2 (ru) 2006-05-27
KR100829297B1 (ko) 2008-05-13
HUP0303714A3 (en) 2007-03-28
US20030166667A1 (en) 2003-09-04
PL363870A1 (en) 2004-11-29
SK1292003A3 (en) 2003-08-05
CA2416706A1 (en) 2002-02-07
BR0112881A (pt) 2003-07-01
HK1054231A1 (zh) 2003-11-21

Similar Documents

Publication Publication Date Title
WO2018081508A1 (en) Memantine combinations and use
NZ299376A (en) Treating tinnitus using piperidine, pyrrolidine or 8-aza-bicyclo[3.2.1]octane derivatives
WO2006049312A1 (ja) 神経因性疼痛治療剤
EP3570940B1 (en) Pridopidine for use in the treatment of fragile x syndrome
EP2288345B1 (en) Psycho-pharmaceuticals
CN110996946A (zh) 用于治疗创伤后应激障碍的制剂
AU579028B2 (en) Anticonvulsant compositions and method
US10864191B2 (en) 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
WO2002043726A1 (en) Method for inducing cognition enhancement by use of trimethyl-bicyclo[2.2.1]heptane derivatives
ZA200300549B (en) Dementia remedies containing 2-aryl-8-oxidihydropurine derivatives as the active ingredient.
JPH05132430A (ja) 薬物従属症及び禁断症状の治療に関するグリシン/nmdaレセプターリガンドの用法
JP7059192B2 (ja) 神経変性疾患の治療に使用するためのイグメシン
CN110996948A (zh) 用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症
ITMI951417A1 (it) Composizioni farmaceutiche e procedimento per la loro preparazione
US6335372B1 (en) Treatment of obsessive compulsive disorder
SK50802006A3 (sk) Kombinovaná farmaceutická kompozícia na inhibíciupoklesu kognitívnych funkcií
US6589996B2 (en) Treatment of disorders relating to the serotonergic system
WO1998046227A1 (en) Composition for treating pain
CA2480266C (en) Use of an alpha2-adrenoreceptor antagonist for cns-related diseases
WO1998046601A1 (en) Composition for treating pain
CA3061243C (en) Idalopirdine-based combinatorial therapies of alzheimer's disease
WO2002043727A1 (en) Treatment of psychiatric disorders with trimethyl-bicyclo[2.2.1]heptane derivatives
Möbius Memantine in Treatment of AD